February 04, 2021
1 min read
Save

FDA accepts NDA for STN10117 for glaucoma, ocular hypertension

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA accepted a new drug application for STN10117 for the treatment of glaucoma and ocular hypertension, Santen and Ube Industries announced in a press release.

STN10117 (DE-117) (omidenepag isopropyl) is an investigational topical ophthalmic solution that offers a new mechanism of action, the release said.

STN10117 was launched in Japan in 2018 as Eybelis ophthalmic solution 0.002% and approved in South Korea in 2019.

The FDA set Nov. 19, 2021, as the PDUFA date.